The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.
The top 5 most-read dermatology content of 2025 on AJMC.com included innovative advances from artificial intelligence ...
ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life ...
Reimbursement policy in the US saw major upheaval in the second half of 2025. New mandates, stalled subsidy negotiations, and pricing pressures created major uncertainty for payers, providers, and ...
Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.
The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...
In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...
A reimbursable, team-based remote blood pressure monitoring program significantly improved hypertension control in patients ...
Here are the most-read “5 things” articles from 2025.
High risk of obstructive sleep apnea (OSA) is linked to a 40% increase in poor mental health outcomes, including depression ...
Sequential BCL2 inhibitor therapy shows initial responses but lacks durability, especially in patients exposed to both BTKi ...
CXCL12 and CXCL13 are potential biomarkers for RSV bronchiolitis severity and recurrence risk, with elevated levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results